BioPharma Dive January 2, 2025
Vertex’s new cystic fibrosis medicine could help extend the company’s market dominance, while Bristol Myers aims to capitalize on a more convenient formulation of its Opdivo immunotherapy.
The Food and Drug Administration ended 2024 with a quartet of notable drug approvals, including three of new medicines that Vertex Pharmaceuticals, Novo Nordisk and Bristol Myers Squibb developed for cystic fibrosis, hemophilia and cancer, respectively.
The approvals concluded a year in which the agency’s main review office cleared 50 novel medicines, less than the 55 in 2023 but toward the higher end of annual totals over the past several years. The record came in 2018, when 59 were cleared by the regulator’s Center for Drug Evaluation and Research. The FDA’s biologics office...
Today's Sponsors
Today's Sponsor